If we achieve revenues from a Covid treatment we will have enough money to instantly fund multiple trials on our own, imo, so for that reason I doubt very much that Don will bring in a partner for a given trial which would require giving up a significant chunk of all multiple potential revenues streams.  

Its a dilema.   Can you structure a deal with a BP where they only get a piece of revenues from the one indication they helped to fund trials for, and not get a piece of revenues from separate indications approved later on?   I'm sure BP would say "If we're in for developing apabetalone for one indication then we're also in for all additional indication revenue streams too".

I'm curious as to whether anyone has thought of a way to define and carve out separate indication revenue streams from a multi-indication single drug.